Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences is conducting a ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...